Jupiter Topco LLC Acquires New Stake in Adaptive Biotechnologies Corporation $ADPT

Jupiter Topco LLC bought a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 46,900 shares of the company’s stock, valued at approximately $1,006,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ADPT. BlackRock Inc. bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $324,735,000. Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Price T Rowe Associates Inc. MD raised its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Finally, Invesco Ltd. boosted its holdings in Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after acquiring an additional 2,216,595 shares during the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $24.28 on Friday. The firm has a market cap of $3.88 billion, a PE ratio of -59.22 and a beta of 2.09. Adaptive Biotechnologies Corporation has a 52-week low of $12.00 and a 52-week high of $26.87. The business’s 50 day moving average price is $23.47 and its two-hundred day moving average price is $17.96. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The company had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same period last year, the business earned ($0.17) EPS. The business’s quarterly revenue was up 21.5% compared to the same quarter last year. On average, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 3,000 shares of Adaptive Biotechnologies stock in a transaction on Monday, August 10th. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the sale, the insider directly owned 396,989 shares of the company’s stock, valued at approximately $9,924,725. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 30,664 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $24.40, for a total transaction of $748,201.60. Following the transaction, the director owned 46,683 shares in the company, valued at $1,139,065.20. This represents a 39.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 2,011,584 shares of company stock valued at $45,765,999. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ADPT shares. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Piper Sandler boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Guggenheim upped their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $24.42.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.